Tag: Gilead Sciences

The “Sexual Revolution:” An Unwitting Instrument of Capitalist Counterrevolution’s Devastating Public Health Legacy

Tina Marie (Ms. Cat)

The so-called “sexual revolution” that began in the 1960s and 1970s, hailed by bourgeois liberals and postmodern academics as a triumph of individual liberation and progressive reform, also became bound up with deeply reactionary phenomenon. From advancing the cause of human emancipation, it became a critical component of the broader social counterrevolution orchestrated by the ruling classes to undermine the potential of the working class. This pseudo-liberation, rooted to a notable extent in the decay of capitalist society, has contributed directly to profound negative impacts on public health, including the explosive proliferation of sexually transmitted infections (STIs), mental health crises, and the commodification of human relationships under the guise of “freedom.”

The “Sexual Revolution:” An Unwitting Instrument of Capitalist Counterrevolution’s Devastating Public Health Legacy

Related:

Lies about the Holodomor, Joseph Stalin, & the U.S.S.R.

Trotskyism

The FDA loves horse medicine if it’s really expensive, still under patent, and toxic (Fauci, Baric, Denison, DTRA & Gilead Sciences)

Tina Marie (Ms. Cat)

The FDA loves horse medicine if it’s really expensive, still under patent, and toxic

Related:

Study shows effectiveness of pill form of remdesivir to treat COVID-19 in mice (Ralph Baric & Gilead Sciences)**

Molnupiravir & Ivermectin’s Equine Connections

An emerging antiviral takes aim at COVID-19

[Molnupiravir] EIDD-2801’s story starts years before the coronavirus crisis. In 2014, Painter and his colleagues at Emory University began a project funded by the Defense Threat Reduction Agency to find an antiviral compound that could fight Venezuelan equine encephalitis virus (VEEV). During the Cold War, both the US and the Soviet Union studied VEEV as a potential biological weapon. Typically transmitted through mosquito bites, VEEV causes high fevers, headaches, and sometimes encephalitis, swelling of the brain that can be deadly.

…

In late 2019, Painter got a contract from the National Institute of Allergy and Infectious Diseases* to move EIDD-2801 into Phase I clinical trials for influenza. The plan was to file an investigational new drug application and find a partner to help with the clinical work.

…

Just as the team was contemplating its next move, word of a virus spreading in Wuhan, China, was starting to make news. One of Painter’s collaborators, UNC coronavirus expert Ralph Baric**, immediately alerted him that the new pathogen was probably a coronavirus—one that EIDD-2801 could potentially combat.

Denison*** says the research team knew a coronavirus outbreak was inevitable. “Every single one of our grants, every single one of our papers predicted that this event was going to happen that’s occurring right now,” he says. “The whole goal of our drug development was to plan for this.”

*Anthony Fauci, director of NIAID.

**Ralph Baric, patents.

***Mark Denison (Denison Lab/Vanderbilt University Medical Center & Gilead Sciences)

A Legacy of Corruption in the FDA and Big Pharma

Tina Marie (Ms. Cat)

By Liam Cosgrove | Mises Wire | September 11, 2021

Our healthcare system is broken, a fact nobody would have disputed in precovid days. Regulatory capture is a reality, and the pharmaceutical industry is fraught with examples. Yet we trusted private-public partnerships to find an optimal solution to a global pandemic, assuming a crisis would bring out the best in historically corrupt institutions.

A Legacy of Corruption in the FDA and Big Pharma

Trust the $cience! 🙄

COVID-19 and the High Cost of Dying

Tina Marie (Ms. Cat)

COVID-19 and the High Cost of Dying

If the FDA approves remdesivir for treating Covid-19, which is by no means guaranteed, Gilead will be able to charge what it likes until 2037. Until then, you can forget about a cheap generic version of the drug.

Related:

Joe Grogan, Trump’s Top Domestic Policy Aide, Leaving White House Next Month

Grogan — who worked as a lobbyist for drugmaker Gilead prior to his time at the White House — has played a significant role in crafting major health policies, including drug pricing, for the Trump administration.